Autolus Therapeutics (AUTL) Q4 2021 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2021 earnings summary
9 Nov, 2026Executive summary
2021 net loss was £102.3m, narrowing from £113.1m in 2020; operating loss was £116.1m vs £128.8m. Cash and cash equivalents were £229.7m at year-end.
Operations remained development-stage, with no product sales; 2021 license revenue was £1.1m, primarily from the Moderna agreement.
Financial highlights
License revenue rose to £1.079m from £0.187m; R&D expense declined to £96.105m from £103.634m and G&A to £23.545m from £27.576m.
Other operating income increased to £4.735m from £2.176m, including £2.629m of lease-termination gains and £1.466m in termination fees.
Income tax benefit was £16.171m vs £19.139m; net loss was £102.255m vs £113.092m.
Net cash used in operating activities was £83.784m; financing activities provided £206.520m, lifting year-end cash and cash equivalents to £229.702m from £112.177m.
Outlook and guidance
Cash of £229.7m was forecast to fund operations through at least 31 May 2023; downside cases included clinical delays, inflation, and missed milestone and R&D tax-credit receipts.
Significant R&D, clinical, regulatory, manufacturing and potential commercialization spending is expected; additional funding will be required before meaningful product-sales revenue, if achieved.
Profitability depends on successful development, regulatory approval and commercialization of product candidates, and revenue sufficient to support the cost base.
Latest events from Autolus Therapeutics
- AUCATZYL scales commercially as margin gains and new indications build the next growth drivers.AUTL
Jefferies Global Healthcare Conference - AUCATZYL growth and expanding obe-cel trials broaden the commercial opportunity.AUTL
Corporate presentation - AUCATZYL revenue rose 95%, gross margin reached 57%, and FY2026 guidance is at least $150M.AUTL
Q3 2026 - IPO-funded cash supports expanding T-cell trials, but losses and clinical risks remain significant.AUTL
Q4 2018 - A £113.5m loss funded a growing T-cell pipeline, with COVID-19 clouding timelines.AUTL
Q4 2019 - Licensing growth and a £316.3m cash balance offset a wider loss, with funding needed beyond June 2024.AUTL
Q4 2022 - Obe-cel advanced toward a 2024 decision, backed by encouraging data and $600M in February proceeds.AUTL
Q4 2023 - Resale registration for 3.5M ADSs linked to a warrant, supporting T cell therapy expansion.AUTL
Registration filing - Q2 2026 revenue surged 119% year-over-year, with gross margin at 55% and guidance raised.AUTL
Q2 2026